Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Wolfgang Kruis(ThyssenKrupp (Germany)), Roland Greinwald(Dr Falk Pharma (Germany)), Olga Alexeeva(Nizhny Novgorod Regional Clinical Hospital named after Semashko), Ralph Müeller(Dr Falk Pharma (Germany)), Michael Vieth(Bayreuth Medical Center), Svetlana V Maksyashina, Britta Siegmund(Humboldt-Universität zu Berlin), О. А. Саблин(Ministry of Emergency Situations), Yury P. Uspenskiy, П. С. Андреев, Konrad Leśniakowski(Wojewódzki Szpital Specjalistyczny we Wrocławiu), Olena Datsenko, Marcin Soboń, Juris Pokrotnieks(Pauls Stradiņš Clinical University Hospital), Ralf Mohrbacher(Dr Falk Pharma (Germany)), Ivan P Kolesnik(Zaporizhzhia National University), Yuriy Mostovoy(Clinical Trial Investigators), В. И. Симаненков(North-Western State Medical University named after I.I. Mechnikov), Sayar Abdulkhakov(Kazan State Medical University), Malgorzata Baluta, Glebs Delmans(Daugavpils University), N. M. Kharchenko(Shupyk National Healthcare University of Ukraine), Neshta Viacheslav(Zaporizhzhia National University), О. Аbrahamovych, Olena Levchenko, A. E. Dorofeyev(Shupyk National Healthcare University of Ukraine), Emese Mihály(Semmelweis University), Л. В. Хіміон(Kyiv City Clinical Oncology Center)
Cited by 15
Related Papers
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558
Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans
|Cell|2019|472
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
|Gastroenterology|2012|378
Monocyte and M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD
|Inflammatory Bowel Diseases|2015|361